银诺医药
INNOGEN

Guangzhou Innogen Pharmaceutical Group Co., Ltd.
廣州銀諾醫藥集團股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2591)

VOLUNTARY ANNOUNCEMENT
BUSINESS UPDATE ON CLINICAL TRIAL
OF CORE PRODUCT IN THE PRC

This announcement is made by Guangzhou Innogen Pharmaceutical Group Co., Ltd. (the "**Company**") to inform the shareholders of the Company (the "**Shareholders**") and potential investors of its recent business development.

As disclosed in the prospectus of the Company dated 7 August 2025, the Company initiated Phase IIb/III clinical trial of the Company's Core Product (i.e. Efsubaglutide Alfa) for the treatment of obesity and being overweight in the People's Republic of China (the "**PRC**") in March 2025. The board (the "**Board**") of directors of the Company (the "**Directors**") is pleased to announce that on 30 September 2025, the Company completed the first patient dosing in the Phase III clinical trial of the Core Product for the treatment of obesity and being overweight in the PRC. The Company plans to enroll approximately 800 participants for such clinical trial.

Cautionary Statement: The Company cannot guarantee that it will be able to ultimately develop and/or market the Core Product for the treatment of obesity and being overweight in the PRC successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
Guangzhou Innogen Pharmaceutical Group Co., Ltd.
Dr. WANG QINGHUA
Chairman of the Board

Shanghai, the PRC, 30 September 2025

As at the date of this announcement, the Board comprises Dr. WANG QINGHUA, Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing as executive Directors; Mr. HO KYUNG SHIK and Mr. Heng Lei as non-executive Directors; and Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony as independent non-executive Directors.